This is where you will find information on the latest updates to the National Clinical Terminology Service products and resources. The details of any changes are included in the relevant release note.
|/library/DH_3445_2021_ClinicalTerminology_SNOMEDCT-AU_ReleaseNote_v20210430.pdf||SNOMED CT-AU Release Note 30 April 2021|
|/library/DH_3446_2021_NCTS_DocumentLibraryReleaseNote_v2.27.pdf||NCTS Document Library Release Note v2.27|
|/library/DH_3319_2020_RCPA_PathologyTerminologyandInformationModels_ReleaseNote_v1.4.pdf||RCPA Pathology Terminology and Information Models Release Note v1.4|
The following resource has been added:
Please refer to the NCTS Document Library Release Note v2.27 above for further details.
NSW Reportable Schedule 4 reference set (added February 2021)
This newly released reference set supports systems with the identification of the AMT Trade Product Unit of Use (TPUU), Containered Trade Product Pack (CTPP), Medicinal Product Unit of Use (MPUU) and Medicinal Product Pack (MPP) concepts that are reportable within New South Wales for Real Time Reporting (RTR) and Real Time Prescription Monitoring (RTPM) requirements.
This reference set complements the existing reportable Schedule 4 reference sets and the Schedule 8 medications reference set. The full description of each reference set can be viewed by selecting it within Reference Sets from the ACCESS tab.
Black Triangle Scheme reference set (added December 2020)
This newly release reference set supports the identification of AMT Trade Product Unit of Use (TPUU) and Containered Trade Product Pack (CTPP) concepts that are associated with medicines where reporting adverse events are encouraged under the Black Triangle Scheme run by the Therapeutic Goods Administration. This reference set can be used by prescribing and dispensing software vendors to identify medications where reporting of adverse events is encouraged under the Black Triangle Scheme. Further details be found in the SNOMED CT-AU Development Approach for Reference Sets v3.4.
List of Medicines for Brand Consideration reference set (added September 2020)
This reference set has been updated to include additional medicines as notified by the Australian Government Department of Health. This reference set enables software vendors to identify AMT Medicinal Product Unit of Use (MPUU) and Medicinal Product Pack (MPP) concepts associated with the List of Medicines for Brand Consideration (LMBC).
The following list contains all COVID-19 specific concepts that are currently available in the SNOMED CT-AU release. They are displayed below as concept ID |Preferred Term| and grouped according to their SNOMED CT concept hierarchy. You can view any additional synonyms to these concepts in the Shrimp Terminology Browser. If you have suggestions for new concepts or synonyms, please complete our online request form (preferred) or send your content request to email@example.com.
1454671000168104 |Recent travel to high risk COVID-19 region|
1465981000168100 |Bilateral interstitial pneumonia| added May 2020
1466021000168105 |Concern about exposure to COVID-19| added May 2020
1466151000168103 |More than two diffuse B-lines on ultrasound of lung| added May 2020
840544004 |Suspected COVID-19|
840546002 |Exposure to COVID-19|
840533007 |SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2)|
840534001 |COVID-19 vaccination|
1454651000168108 |COVID-19 serology|
1454581000168100 |Bronchoalveolar lavage fluid COVID-19 nucleic acid assay|
1454561000168109 |Sputum COVID-19 nucleic acid assay|
1454491000168101 |Oropharyngeal swab COVID-19 nucleic acid assay|
1454411000168105 |Nasopharyngeal swab COVID-19 nucleic acid assay|
1454401000168107 |Home isolation|
1462681000168102 |Rapid COVID-19 antibody detection test|
1462701000168104 |COVID-19 IgM measurement|
1462741000168102 |COVID-19 IgG measurement|
1466171000168107 |ARDSNet Mechanical Ventilation Protocol| added May 2020
1466161000168101 |Permissive hypercapnia ventilation| added May 2020
1466191000168108 |Pleural fluid COVID-19 nucleic acid assay| added May 2020
1466181000168105 |Saliva COVID-19 nucleic acid assay| added May 2020
1480481000168103 | COVID-19 viral culture | added July 2020
1454661000168105 |COVID-19 Clinic and Testing Centre|
840536004 |Antigen of SARS-CoV-2|
840535000 |Antibody to SARS-CoV-2|
Australian Medicines Terminology
1480881000168101 | Veklury 100 mg powder for injection, 1 vial | added July 2020
1480791000168108 | Veklury 100 mg/20 mL injection, 20 mL vial | added July 2020
1525001000168109 | BNT162b2 mRNA | added February 2021
1525021000168100 | COVID-19 mRNA vaccine | added February 2021
1525031000168102 | COVID-19 mRNA vaccine injection, 0.45 mL vial | added February 2021
1525051000168108 | COVID-19 mRNA vaccine injection, 195 x 0.45 mL vials | added February 2021
1525011000168107 | Comirnaty | added February 2021
1525041000168106 | Comirnaty Multidose injection, 0.45 mL vial | added February 2021
1525061000168105 | Comirnaty Multidose injection, 195 x 0.45 mL vials | added February 2021
1525071000168104 | Comirnaty Multidose injection, 195 x 0.45 mL vials | added February 2021
1527281000168103 | ChAdOx1-S viral vector | added February 2021
1527311000168101 | COVID-19 viral vector vaccine | added February 2021
1527321000168108 | COVID-19 viral vector vaccine, 5 mL vial | added February 2021
1527341000168102 | COVID-19 viral vector vaccine, 10 x 5 mL vials | added February 2021
1527271000168101 | COVID-19 Vaccine (AstraZeneca) | added February 2021
1527331000168106 | COVID-19 Vaccine (AstraZeneca) Multidose injection, 5 mL vial | added February 2021
1527351000168100 | COVID-19 Vaccine (AstraZeneca) Multidose injection, 10 x 5 mL vials | added February 2021
1527361000168103 | COVID-19 Vaccine (AstraZeneca) Multidose injection, 10 x 5 mL vials | added February 2021
By operation of the Public Governance, Performance and Accountability (Establishing the Australian Digital Health Agency) Rule 2016, on 1 July 2016, all the assets and liabilities of NEHTA will vest in the Australian Digital Health Agency. In this website, on and from 1 July 2016, all references to “National E-Health Transition Authority” or “NEHTA” will be deemed to be references to the Australian Digital Health Agency.